Technical Analysis for RVNC - Revance Therapeutics, Inc.

Grade Last Price % Change Price Change
grade C 15.07 -0.66% -0.10
RVNC closed down 0.66 percent on Wednesday, November 13, 2019, on 70 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Down
See historical RVNC trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Stochastic Reached Oversold Weakness 0.00%
Oversold Stochastic Weakness 0.00%
20 DMA Resistance Bearish -0.66%
Shooting Star Candlestick Bearish -0.66%
1,2,3 Pullback Bullish Bullish Swing Setup -0.66%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -0.66%

Older signals for RVNC ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Revance Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic applications worldwide. Its lead product candidate is RT001, a topical gel formulation of botulinum toxin type A, which is in Phase III clinical trials for the treatment of crow's feet lines; has completed initial Phase II clinical trials for the treatment of hyperhidrosis and for the prevention of migraine headache; and has completed Phase I clinical trials for the treatment of other indications, such as neuropathic pain and rhinitis. The company is also developing RT002, a novel injectable formulation of botulinum toxin type A, which is being tested in the four-cohort Phase I/II clinical dose escalation trials for the treatment of glabellar lines. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is based in Newark, California.
Biopharmaceutical Pain Drugs Migraine Plastic Surgery Toxins Botulinum Toxin Botulism Hyperhidrosis Neurotoxins Rhinitis
Is RVNC a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 24.99
52 Week Low 10.0
Average Volume 363,383
200-Day Moving Average 13.6141
50-Day Moving Average 13.9578
20-Day Moving Average 15.385
10-Day Moving Average 15.393
Average True Range 0.6767
ADX 31.66
+DI 26.0094
-DI 14.8484
Chandelier Exit (Long, 3 ATRs ) 14.6599
Chandelier Exit (Short, 3 ATRs ) 15.8401
Upper Bollinger Band 15.8366
Lower Bollinger Band 14.9334
Percent B (%b) 0.15
BandWidth 5.870653
MACD Line 0.4062
MACD Signal Line 0.5477
MACD Histogram -0.1415
Fundamentals Value
Market Cap 464.44 Million
Num Shares 30.8 Million
EPS -3.44
Price-to-Earnings (P/E) Ratio -4.38
Price-to-Sales 2609.34
Price-to-Book 4.85
PEG Ratio -0.61
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 15.75
Resistance 3 (R3) 15.78 15.58 15.63
Resistance 2 (R2) 15.58 15.41 15.57 15.59
Resistance 1 (R1) 15.33 15.31 15.23 15.30 15.56
Pivot Point 15.13 15.13 15.09 15.12 15.13
Support 1 (S1) 14.88 14.96 14.78 14.85 14.58
Support 2 (S2) 14.68 14.86 14.67 14.55
Support 3 (S3) 14.43 14.68 14.51
Support 4 (S4) 14.40